{
    "ticker": "PDSB",
    "name": "PDS Biotechnology Corporation",
    "description": "PDS Biotechnology Corporation is a clinical-stage immunotherapy company dedicated to developing innovative therapies for cancer and infectious diseases. Founded in 2015 and headquartered in Princeton, New Jersey, PDSB focuses on harnessing the power of the immune system to target and destroy cancer cells. Their lead product candidate, PDS0101, is a novel immunotherapy designed to treat human papillomavirus (HPV)-related cancers, including cervical cancer. PDSB's proprietary platform, Versamune\u00ae, enhances the immune response to tumor-associated antigens, aiming to generate a robust and durable immune reaction. The company is committed to advancing its pipeline through rigorous clinical trials and collaborations with leading research institutions and pharmaceutical partners. PDSB's mission is to improve patient outcomes and quality of life by providing innovative treatment options that leverage the body's natural defenses against diseases. With a strong focus on research and development, PDS Biotechnology is poised to make significant contributions to the field of immunotherapy and oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Princeton, New Jersey, USA",
    "founded": "2015",
    "website": "https://www.pdsbiotech.com",
    "ceo": "Dr. Frank Bedu-Addo",
    "social_media": {
        "twitter": "https://twitter.com/PDSBiotech",
        "linkedin": "https://www.linkedin.com/company/pds-biotechnology/"
    },
    "investor_relations": "https://investors.pdsbiotech.com",
    "key_executives": [
        {
            "name": "Dr. Frank Bedu-Addo",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael L. W. T. Heller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapies",
            "products": [
                "PDS0101"
            ]
        }
    ],
    "seo": {
        "meta_title": "PDS Biotechnology Corporation | Immunotherapies for Cancer",
        "meta_description": "PDS Biotechnology Corporation is a clinical-stage company developing innovative immunotherapies for cancer and infectious diseases, focusing on enhancing the immune response.",
        "keywords": [
            "PDS Biotechnology",
            "Immunotherapy",
            "Cancer Treatment",
            "HPV",
            "Clinical Trials",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is PDS Biotechnology known for?",
            "answer": "PDS Biotechnology is known for developing innovative immunotherapies for cancer, particularly targeting HPV-related cancers."
        },
        {
            "question": "Who is the CEO of PDS Biotechnology?",
            "answer": "Dr. Frank Bedu-Addo is the CEO of PDS Biotechnology Corporation."
        },
        {
            "question": "Where is PDS Biotechnology headquartered?",
            "answer": "PDS Biotechnology is headquartered in Princeton, New Jersey, USA."
        },
        {
            "question": "What is the lead product candidate of PDS Biotechnology?",
            "answer": "The lead product candidate of PDS Biotechnology is PDS0101, an immunotherapy for HPV-related cancers."
        },
        {
            "question": "When was PDS Biotechnology founded?",
            "answer": "PDS Biotechnology was founded in 2015."
        }
    ],
    "competitors": [
        "RIGL",
        "IMTX",
        "NK",
        "CLVS"
    ],
    "related_stocks": [
        "MRNA",
        "BNTX",
        "NVAX",
        "SNY"
    ]
}